AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury

Journal of Clinical Investigation

Volumn 114, Issue 4, 2004, Pages 495-503

  Russell III, Raymond R ^a   Li, Ji ^a   Coven, David L ^a   Pypaert, Marc ^a   Zechner, Christoph ^a   Palmeri, Monica ^a   Giordano, Frank J ^a   Mu, James ^b   Birnbaum, Morris J ^b   Young, Lawrence H ^a,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Fitkin 3 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CASPASE 3; GLUCOSE; GLUCOSE TRANSPORTER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; 5' AMP ACTIVATED PROTEIN KINASE; 5'-AMP-ACTIVATED PROTEIN KINASE; MULTIENZYME COMPLEX; PROTEIN SERINE THREONINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; ENZYME INHIBITION; FATTY ACID OXIDATION; GLUCOSE TRANSPORT; GLYCOLYSIS; HEART DISEASE; HEART FAILURE; HEART HYPERTROPHY; HEART INFARCTION PREVENTION; HEART INJURY; HEART LEFT VENTRICLE CONTRACTION; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; MALE; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; TRANSGENIC MOUSE; ANIMAL; C57BL MOUSE; COMPARATIVE STUDY; GENETICS; METABOLISM;

ANIMALS; APOPTOSIS; GLUCOSE; GLYCOLYSIS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MULTIENZYME COMPLEXES; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; PROTEIN-SERINE-THREONINE KINASES;

EID: 78149279712     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI19297     Document Type: Article

References (62)

1. Hardie, D., Scott, J., Pan, D., and Hudson, E. 2003. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett. 546:113-120.
2. Kemp, B.E., et al. 2003. AMP-activated protein kinase, super metabolic regulator. Biochem Soc. Trans. 31:162-168.
3. Kudo, N., et al. 1996. Characterization of 5′AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Biochim. Biophys. Acta. 1301:67-75.
4. Winder, W., and Hardie, D. 1996. Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am. J. Physiol. 270:E299-E304.
5. Russell, R., Bergeron, R., Shulman, G., and Young, L. 1999. Translocation of myocardial GLUT4 and increased glucose uptake through activation of AMP-activated protein kinase by AICAR. Am. J. Physiol. 277:H643-H649.
6. Marsin, A.S., et al. 2000. Phosphorylacion and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr. Biol. 10:1247-1255.
7. Merrill, G., Kurth, E., Hardie, D., and Winder, W. 1997. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am. J. Physiol. 273:E1107-E1112.
8. Fryer, L.G., et al. 2002. Characterization of the role of the AMP-activated protein kinase in the stimulation of glucose transport in skeletal muscle cells. Biochem. J. 363:167-174.
9. Kurth-Kraczek, E., Hirshman, M., Goodyear, L., and Winder, W. 1999. 5′ AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes. 48:1667-1671.
10. Ojuka, E.O., Nolte, L.A., and Holloszy, J.O. 2000. Increased expression of GLUT-4 and hexokinase in rat epitrochlearis muscles exposed to AICAR in vitro. J. Appl. Physiol. 88:1072-1075.
11. Holmes, B.F., Kurth-Kraczek, E.J., and Winder, W.W. 1999. Chronic activation of 5′-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogenin muscle. J. Appl. Physiol. 87:1990-1995.
12. Zhou, M., Lin, B.Z., Coughlin, S., Vallega, G., and Pilch, P.F. 2000. UCP-3 expression in skeletal muscle: effects of exercise, hypoxia, and AMP-activated protein kinase. Am. J. Physiol. 279:E622-E629.
13. Bergeron, R., et al. 2001. Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis. Am. J. Physiol. 281:E1340-E1346.
14. Zong, H., et al. 2002. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc. Natl. Acad. Sci. U. S. A. 99:15983-15987.
15. Young, L., et al. 1997. Low flow ischemia leads to translocation of canine heart GLUT-4 and GLUT-1 glucose transporters to the sarcolemma in vivo. Circulation. 95:415-422.
16. Hayashi, T., Hirshman, M.F., Kurth, E.J., Winder, W.W., and Goodyear, L.J. 1998. Evidence for 5′ AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes. 47:1369-1373.
17. Hayashi, T., et al. 2000. Metabolic stress and altered glucose transport: activation of AMP-activated protein kinase as a unifying coupling mechanism. Diabetes. 49:527-531.
18. Mu, J., Brozinick, J.T., Jr., Valladares, O., Bucan, M., and Birnbaum, M.J. 2001. A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol. Cell. 7:1085-1094.
19. Kudo, N., Barr, A., Barr, R., Desai, S., and Lopaschuk, G. 1995. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J. Biol. Chem. 270:17513-17520.
20. Randle, P., Newsholme, E., and Garland, P. 1964. Regulation of glucose uptake by muscle. 8. Effects of fatty acids, ketone bodies and pyruvate and of alloxan-diabetes and starvation on the uptake and metabolic rate of glucose in rat heart and diaphragm muscles. Biochem. J. 93:652-665.
21. Sambandam, N., and Lopaschuk, G.D. 2003. AMP-activated protein kinase (AMPK) control of fatty acid and glucose metabolism in the ischemic heart. Prog. Lipid Res. 42:238-256.
22. Hopkins, T.A., Dyck, J.R., and Lopaschuk, G.D. 2003. AMP-activated protein kinase regulation of fatty acid oxidation in the ischaemic heart. Biochem. Soc.Trans. 31:207-212.
23. Morrow, V.A., et al. 2003. Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. J. Biol. Chem. 278:31629-31639.
24. Katz, E.B., Stenbit, A.E., Hatton, K., DePinho, R., and Charron, M.J. 1995. Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4. Nature. 377:151-155.
25. Zisman, A., et al. 2000. Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat. Med. 6:924-928.
26. Shioi, T., et al. 2000. The conserved phosphoinositide 3-kinase pathway determines heartsize in mice. EMBO J. 19:2537-2548.
27. Watanabe, K., et al. 2000. Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiac toxicity. J. Biol. Chem. 275:22293-22299.
28. Arad, M., et al. 2003. Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation. 107:2850-2856.
29. Krijnen, P.A.J., et al. 2002. Apoptosis in myocardial ischaemia and infarction. J. Clin. Pathol. 55:801-811.
30. Xing, Y., et al. 2003. Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative α2 subunit of AMP-activated protein kinase. J. Biol. Chem. 278:28372-28377.
31. Morgan, H., Cadenas, E., Regen, D., and Park, C. 1961. Regulation of glucose uptake in muscle. II. Rate-Limiting steps and effects of insulin and anoxia in heart muscle from diabetic rats. J. Biol. Chem. 236:262-268.
32. McVeigh, J., and Lopaschuk, G. 1990. Dichloroacetate stimulation of glucose oxidation improves recovery of perfused working heart. Am. J. Physiol. 259:H1070-H1085.
33. Lopaschuk, G.D., Spafford, M.A., Davies, N.J., and Wall, S.R. 1990. Glucose and palmitate oxidation in isolated working rat hearts reperfused after a period of transient global ischemia. Circ. Res. 66:546-553.
34. Lopaschuk, G., and Saddik, M. 1992. The relative contribution of glucose and fatty acids to ATP production in hearts reperfused following ischemia. Mol. Cell. Biochem. 116:111-116.
35. Tian, R., and Abel, E.D. 2001. Responses of GLUT4-deficient hearts to ischemia underscore the importance of glycolysis. Circulation. 103:2961-2966.
36. Ramasamy, R., Hwang, Y.C., Whang, J., and Bergmann, S.R. 2001. Protection of ischemic hearts by high glucose is mediated, in part, by GLUT-4. Am. J. Physiol. 281:H290-H297.
37. King, L.M., and Opie, L.H. 1998. Glucose and glycogen utilisation in myocardial ischemia-changes in metabolism and consequences for the myocyte. Mol. Cell. Biochem. 180:3-26.
38. McCormack, J., Barr, R., Wolff, A., and Lopaschuk, G. 1996. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation. 93:135-142.
39. 2. Biochem. Biophys. Res. Commun. 287:92-97.
40. Malhotra, R., and Brosius, F. 1999. Glucose uptake and glycolysis reduce hypoxia-induced apoptosis in cultured neonatal rat cardiac myocytes. J. Biol. Chem. 274:12567-12575.
41. Loberg, R.D., Vesely, E., and Brosius, F.C., III. 2002. Enhanced glycogen synthase kinase-3β activity mediates hypoxia-induced apoptosis of vascular smooth muscle cells and is prevented by glucose transport and metabolism. J. Biol. Chem. 277:41667-41673.
42. Malhotra, R., Lin, Z., Vincenz, C., and Brosius, F.C., III. 2001. Hypoxia induces apoptosis via two independent pathways in Jurkat cells: differential regulation by glucose. Am J. Physiol. 281:C1596-C1603.
43. Blazquez, C., Geelen, M.J., Velasco, G., and Guzman, M. 2001. The AMP-activated protein kinase prevents ceramide synthesis de novo and apoptosis in astrocytes. FEBS Lett. 489:149-153.
44. Stefanelli, C., et al. 1998. Inhibition of glucocorticoid-induced apoptosis with 5-aminoimidazole-4-carboxamide ribonucleoside, a cell-permeable activator of AMP-activated protein kinase. Biochem. Biophys. Res. Commun. 243:821-826.
45. Ido, Y., Carling, D., and Ruderman, N. 2002. Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation. Diabetes. 51:159-167.
46. Meisse, D., et al. 2002. Sustained activation of AMP-activated protein kinase induces c-Jun N-terminal kinase activation and apoptosis in liver cells. FEBS Lett. 526:38-42.
47. Lopez, J.M., Santidrian, A.F., Campas, C., and Gil, J. 2003. 5-Aminoimidazole-4-carboxamide riboside induces apoptosis in Jurkat cells, but the AMP-activated protein kinase is not involved. Biochem. J. 370:1027-1032.
48. Mangano, D.T. 1997. Effects of acadesineon myocardial infarction, stroke, and death following surgery. A meta-analysis of the 5 international randomized trials. The Multicencer Study of Perioperative Ischemia (McSPI) Research Group. JAMA. 277:325-332.
49. Zhao, Z.Q., et al. 1995. Acadesine reduces myocardial infarct size by an adenosine mediated mechanism. Cardiovasc. Res. 29:495-505.
50. Jorgensen, S.B., et al. 2004. Knockout of the alpha2 but not alpha1 5′-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4- carboxamide-1-beta-4-ribofuranosidebut not contraction-induced glucose uptake in skeletal muscle. J. Biol. Chem. 279:1070-1079.
51. Wojtaszewski, J.F., Jorgensen, S.B., Hellsten, Y., Hardie, D.G., and Richter, E.A. 2002. Glycogen-dependent effects of 5-aminoimidazole-4-carboxamide (AICA)-riboside on AMP-activated protein kinase and glycogen synthase activities in rat skeletal muscle. Diabetes. 51:284-292.
52. Blair, E., et al. 2001. Mutations in the γ2 subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum. Mol. Genet. 10:1215-1220.
53. Arad, M., et al. 2002. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J. Clin. Invest. 109:357-362. doi:10.1172/JCI200214571.
54. Gollob, M.H., et al. 2001. Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy. Circulation. 104:3030-3033.
55. Gardin, J.M., Siri, F.M., Kitsis, R.N., Edwards, J.G., and Leinwand, L.A. 1995. Echocardiographic assessment of left ventricular mass and systolic function in mice. Circ. Res. 76:907-914.
56. Tanaka, N., et al. 1996. Transthoracic echocardiography in models of cardiac disease in the mouse. Circulation. 94:1109-1117.
57. Huang, Y., et al. 2004. Cardiac myocyte-specific HIF-1α deletion alters vascularization, energy availability, calcium flux and contractility in the normoxic heart. FASEB J. 18:1138-1140.
58. Katz, J., and Dunn, A. 1967. Glucose-2-t as a tracer for glucose metabolism. Biochemistry. 6:1-5.
59. Lopaschuk, G.D., and Barr, R.L. 1997. Measurements of fatty acid and carbohydrate metabolism in the isolated working rat heart. Mol. Cell. Biochem. 172:137-147.
60. Russell, R., Nguyen, V., Mrus, J., and Taegtmeyer, H. 1992. Fasting and lactate unmask insulin responsiveness in the isolated working rat heart. Am. J. Physiol. 263:E556-E561.
61. Bergmeyer, H. 1974. Methods of enzymatic analysis. 3rd edition. Verlag-Chemie, Weinheim/Academic Press Inc. New York, New York, USA. 2000 pp.
62. Coven, D.L., et al. 2003. Physiological role of AMP-activated protein kinase in the heart: graded activation during exercise. Am. J. Physiol. 285:E629-E636.